Dr. Reddy’s Plans Calibrated Emerging Markets Redux
This article was originally published in PharmAsia News
Executive Summary
Enthused by growth opportunities, the Indian drug maker is drawing up plans for a re-entry in certain key emerging markets. The renewed outlook comes at the back of an earlier deal with GSK, which experts believe did not reach anywhere near the potential expected from it.